Overview

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein D

Status:
Completed
Trial end date:
2021-10-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.